Home › Funds › Stonepine Capital Management, LLC › PHAT
Stonepine Capital Management, LLC position in PHAT
PHATHOM PHARMACEUTICALS INC · Health Care
Stonepine Capital Management, LLC reported holding 100,000 shares of PHAT (PHATHOM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$1.2M, representing 0.96% of its reported portfolio and ranking #26 among its reported holdings. Stonepine Capital Management, LLC has disclosed PHAT holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Stonepine Capital Management, LLC's PHAT position evolved
Stonepine Capital Management, LLC first disclosed a stake in PHAT in Q1 2026 at 50,010 shares (US$556K). The position peaked in Q3 2026 at 100,000 shares, worth US$1.2M. Across 3 filings, Stonepine Capital Management, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 100,000 shares valued at US$1.2M — an increase of 14,990 shares quarter over quarter.. Notable position changes include a 70% increase in Q2 2026 (shares fell 33% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 50.01K | $555.61K | New |
| Q2 2026 | 85.01K | $922.36K | Add |
| Q3 2026 | 100.00K | $1.25M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHAT and 13F data
PHAT (PHATHOM PHARMACEUTICALS INC) is a Health Care company. 28 other funds we track also report a position in PHAT — the largest reported positions include Frazier Life Sciences Management, L.P. (US$135.3M), Medicxi Ventures Management (Jersey) Ltd (US$54.5M), Carlyle Group Inc. (US$25.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHAT
- Frazier Life Sciences Management, L.P. 12.47M sh · $135.26M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 7.46M sh · $54.49M · Q3 2026
- Carlyle Group Inc. 3.50M sh · $25.53M · Q3 2026
- NEA Management Company, LLC 1.96M sh · $21.27M · Q2 2026
- 683 Capital Management, LLC 1.85M sh · $20.07M · Q2 2026
- Catalys Pacific, LLC 1.88M sh · $13.74M · Q3 2026
- Propel Bio Management, LLC 1.11M sh · $8.07M · Q3 2026
- EcoR1 Capital, LLC 625.00K sh · $6.78M · Q2 2026
More on Stonepine Capital Management, LLC
FAQ
How long has Stonepine Capital Management, LLC held PHAT?
Stonepine Capital Management, LLC has disclosed PHAT holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Stonepine Capital Management, LLC's current position in PHAT?
As of Q3 2026, Stonepine Capital Management, LLC holds 100.00K shares of PHAT (PHATHOM PHARMACEUTICALS INC), valued at $1.25M, representing 0.96% of its reported portfolio and ranking #26.
Has Stonepine Capital Management, LLC been buying or selling PHAT?
In the latest 13F filing (Q3 2026), Stonepine Capital Management, LLC increased its position in PHAT. The position peaked in Q3 2026 at 100.00K shares.
Which other funds hold PHAT?
Other major institutional holders of PHAT include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Carlyle Group Inc., among 28 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.